Spoken Alpha
HRTX
HERON THERAPEUTICS, INC. /DE/
Overview
HERON THERAPEUTICS, INC. /DE/ is a Healthcare company operating in Biotechnology with a $82.9M market cap.
HRTX missed consensus EPS by 1.0% in Q1 FY2026, reported May 10, 2026.
19 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-112 Q&A exchanges
- Q4 FY2025Earnings2026-02-265 Q&A exchanges
- Q3 FY2025Earnings2025-11-0411 Q&A exchanges
- Q2 FY2025Earnings2025-08-087 Q&A exchanges
- Q1 FY2025Earnings2025-05-067 Q&A exchanges
- Q4 FY2024Earnings2025-02-2713 Q&A exchanges
- Q3 FY2024Earnings2024-11-127 Q&A exchanges
- Q2 FY2024Earnings2024-08-099 Q&A exchanges
- Q1 FY2024Earnings2024-05-0710 Q&A exchanges
- Q4 FY2023Earnings2024-03-128 Q&A exchanges
- Q3 FY2023Earnings2023-11-149 Q&A exchanges
- Q2 FY2023Earnings2023-08-1414 Q&A exchanges
- Q1 FY2023Earnings2023-05-1114 Q&A exchanges
- Q4 FY2022Earnings2023-03-2315 Q&A exchanges
- Q3 FY2022Earnings2022-11-0811 Q&A exchanges
- Q2 FY2022Earnings2022-08-0916 Q&A exchanges
- Q1 FY2022Earnings2022-05-0910 Q&A exchanges
- Q4 FY2021Earnings2022-02-288 Q&A exchanges
- Q3 FY2021Earnings2021-11-0318 Q&A exchanges
History
Earnings history
- Q1 FY20262026-05-10EPS$-0.04 vs $-0.02-100.0%Rev$34.7M vs ——EODHD
- Q4 FY20252026-03-03EPS$-0.02 vs $-0.01-33.3%Rev$40.6M vs ——EODHD
- Q3 FY20252025-11-03EPS$-0.10 vs $-0.01-100.0%Rev$38.2M vs ——EODHD
- Q2 FY20252025-08-07EPS$-0.02 vs $-0.01-100.0%Rev$37.2M vs ——EODHD
- Q1 FY20252025-05-04EPS$0.01 vs $-0.01+100.0%Rev$38.9M vs ——EODHD
- Q4 FY20242025-03-09EPS$0.02 vs $-0.03+100.0%Rev$40.8M vs ——EODHD
- Q3 FY20242024-11-11EPS$-0.03 vs $-0.03-5.7%Rev$32.8M vs ——EODHD
- Q2 FY20242024-08-05EPS$-0.06 vs $-0.04-50.0%Rev$36.0M vs ——EODHD
- Q1 FY20242024-05-06EPS$-0.02 vs $-0.09+77.8%Rev$34.7M vs ——EODHD
- Q4 FY20232024-03-11EPS$-0.07 vs $-0.16+56.3%Rev$34.2M vs ——EODHD
- Q3 FY20232023-11-13EPS$-0.17 vs $-0.29+41.4%Rev$31.4M vs ——EODHD
- Q2 FY20232023-08-13EPS$-0.35 vs $-0.23-52.2%Rev$31.8M vs ——EODHD
- Q1 FY20232023-05-10EPS$-0.27 vs $-0.20-35.0%Rev$29.6M vs ——EODHD
- Q4 FY20222023-03-22EPS$-0.17 vs $-0.28+39.3%Rev$30.0M vs ——EODHD
- Q3 FY20222022-11-07EPS$-0.38 vs $-0.380.0%Rev$26.6M vs ——EODHD
- Q2 FY20222022-08-08EPS$-0.55 vs $-0.50-10.0%Rev$27.6M vs ——EODHD
- Q1 FY20222022-05-08EPS$-0.63 vs $-0.48-31.3%Rev$23.5M vs ——EODHD
- Q4 FY20212022-02-27EPS$-0.54 vs $-0.58+6.9%Rev$20.7M vs ——EODHD
- Q3 FY20212021-11-02EPS$-0.51 vs $-0.61+16.4%Rev$23.2M vs ——EODHD
- Q2 FY20212021-08-08EPS$-0.62 vs $-0.55-12.7%Rev$22.4M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-10 | $-0.04 | $-0.02 | -100.0% | $34.7M | — | — | EODHD |
| Q4 FY2025 | 2026-03-03 | $-0.02 | $-0.01 | -33.3% | $40.6M | — | — | EODHD |
| Q3 FY2025 | 2025-11-03 | $-0.10 | $-0.01 | -100.0% | $38.2M | — | — | EODHD |
| Q2 FY2025 | 2025-08-07 | $-0.02 | $-0.01 | -100.0% | $37.2M | — | — | EODHD |
| Q1 FY2025 | 2025-05-04 | $0.01 | $-0.01 | +100.0% | $38.9M | — | — | EODHD |
| Q4 FY2024 | 2025-03-09 | $0.02 | $-0.03 | +100.0% | $40.8M | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.03 | $-0.03 | -5.7% | $32.8M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-0.06 | $-0.04 | -50.0% | $36.0M | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $-0.02 | $-0.09 | +77.8% | $34.7M | — | — | EODHD |
| Q4 FY2023 | 2024-03-11 | $-0.07 | $-0.16 | +56.3% | $34.2M | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.17 | $-0.29 | +41.4% | $31.4M | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-0.35 | $-0.23 | -52.2% | $31.8M | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.27 | $-0.20 | -35.0% | $29.6M | — | — | EODHD |
| Q4 FY2022 | 2023-03-22 | $-0.17 | $-0.28 | +39.3% | $30.0M | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-0.38 | $-0.38 | 0.0% | $26.6M | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-0.55 | $-0.50 | -10.0% | $27.6M | — | — | EODHD |
| Q1 FY2022 | 2022-05-08 | $-0.63 | $-0.48 | -31.3% | $23.5M | — | — | EODHD |
| Q4 FY2021 | 2022-02-27 | $-0.54 | $-0.58 | +6.9% | $20.7M | — | — | EODHD |
| Q3 FY2021 | 2021-11-02 | $-0.51 | $-0.61 | +16.4% | $23.2M | — | — | EODHD |
| Q2 FY2021 | 2021-08-08 | $-0.62 | $-0.55 | -12.7% | $22.4M | — | — | EODHD |
Source: EODHD. HRTX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks HRTX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.27 | $2.41 | -5.9% | -3.4% | -5.9% |
| Q4 FY2026 | $2.02 | $2.51 | -19.7% | +5.7% | +5.2% |
| Q3 FY2026 | $2.09 | $2.50 | -16.2% | +5.3% | +7.3% |
| Q2 FY2026 | $2.52 | $2.73 | -7.7% | +4.1% | +5.1% |
| Q1 FY2025 | $2.42 | $2.75 | -12.0% | +0.4% | +2.4% |
| Q4 FY2025 | $2.04 | $2.56 | -20.2% | +0.7% | +2.6% |
| Q3 FY2025 | $2.32 | $2.55 | -9.1% | +4.9% | +4.8% |
| Q2 FY2025 | $2.33 | $2.57 | -9.4% | +0.9% | -0.9% |
| Q1 FY2024 | $2.42 | $2.71 | -10.7% | +1.9% | +4.1% |
| Q4 FY2024 | $2.16 | $2.64 | -18.1% | +1.1% | +2.2% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Craig A CollardCEO11 mo12 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last guidance raise Q1 FY2026
- Ira DuarteCFO11 mo12 callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • last call held guidance Q2 FY2026
- Mark Earl HensleyCOO5 mono recorded callsCurrentSample
COO since 2026 • 1/2 beats (50%) • guidance suspended Q3 FY2026
- William P ForbesEVP, Chief Development Officer11 mo7 callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last call held guidance Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for HRTX.
$ curl https://api.spokenalpha.com/v1/companies/HRTXFAQ
Frequently asked about HRTX
Where can I find HERON THERAPEUTICS, INC. /DE/'s (HRTX) earnings call transcripts?
Spoken Alpha indexes HRTX's earnings call transcripts at https://spokenalpha.com/companies/HRTX. Each call links to attributed speakers and parsed analyst Q&A. HERON THERAPEUTICS, INC. /DE/'s own investor relations page is at https://www.herontx.com/investors/.
When was HERON THERAPEUTICS, INC. /DE/'s most recent earnings call?
HERON THERAPEUTICS, INC. /DE/ (HRTX) held its most recent earnings call on 2026-05-11, covering fiscal Q1 2026.
What sector is HRTX in?
HERON THERAPEUTICS, INC. /DE/ (HRTX) operates in the Healthcare sector (Biotechnology industry).